MaaT Pharma: positive data in graft-versus-host disease

(CercleFinance.com) - On Monday, MaaT Pharma announced positive data for the treatment of acute gastrointestinal graft-versus-host disease (GI-aGvH).


The biotech company reports that the Compassionate Access Program (CAP) showed that 140 patients with the steroid-refractory or steroid-dependent form of the disease treated with its MaaT013 had an overall survival rate of 54% at six months, 47% at 12 months and 42% at 18 months.

In third-line treatment, results demonstrated even greater efficacy, with a survival rate of 76% at 12 months for MaaT013 responders, compared with 6% for non-responders.

At 18 months, overall survival reached 64% in this sub-category, compared with 6% in non-responders.

MaaT, which anticipates positive results for its Phase 3 study and a potential commercial launch in 2026, explains that its objective is to capture a substantial share of the third-line patient market, which it believes would mark a "turning point" in the management of this pathology.

These results are due to be unveiled during an oral presentation at the annual meeting of the European Society of Blood and Marrow Transplantation (EBMT), currently being held in Glasgow.

The share price advanced by just 0.2% following these positive data. The share price had, it is true, made good progress at the beginning of April, thanks to a favorable note from Gilbert Dupont analysts, who had initiated coverage of the stock with a buy recommendation and a price target of 16 euros.

Copyright (c) 2024 CercleFinance.com. All rights reserved.